Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

TSX:BCT - Post by User

Briacell Therapeutics Corp.

Bullboard Posts

Comment by Pugsrock2on Apr 04, 2019 12:20am

112 Views

Post# 29580135

RE:RE:RE:RE:RE:Bondarenko

I agree that Jamieson is going to be very positive for the company and he must see lots of potential to jump in and buy up 20M + shares. Not sure how active he would have been in discussions with Incyte. I image Dr William's still has many contacts there from his days working for them. Maybe easier pathway for briacell to deal with incyte over Merck and use Incytes keytruda like product going forward

Bullboard Posts

Odd Burger to add 40 locations in Florida